Corkery 2018: Ibogaine Fatalities & Practical Dangers (*Progress in Brain Research*) — Fatality Literacy, Not Efficacy

Definition box

Definition: Corkery J.M. (2018) published the chapter *Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers* in *Progress in Brain Research* (242:217–257; doi: 10.1016/bs.pbr.2018.08.005; PMID 30471681). Among 2016–2020 citable sources, this is a primary peer-reviewed fatality-update / risk-benefit chapter summarizing known ibogaine-associated deaths (Corkery updates the count to 33 known deaths, including 5 in the UK), balancing purported detoxification benefits against serious adverse effects driven by undiagnosed comorbidity, concomitant drugs, and non-medical settings. It is a review/chapter, not a new prospective cohort, not a cure claim, and not proof of physician-supervised psychoactive IV ibogaine infusion. Earlier forensic case series (e.g., Alper/Stajić/Gill 2012) remain foundational; Corkery 2018 is the best in-window single-author fatality synthesis for SEO citation. Ibogaine is U.S. Schedule I and not FDA-approved. QTc risk is central.

Quotable answer (57 words)

Corkery’s 2018 Progress in Brain Research chapter updates ibogaine-associated fatalities to 33 known deaths, including five in the UK, and stresses careful risk assessment before any use. Fatality reviews are not efficacy trials and not psychoactive IV ibogaine infusion proof. Schedule I; not FDA-approved; cardiac screening is non-negotiable.

Why this paper-spoke exists

Marketing pages soft-pedal deaths as “old news” or “only impure bark.” Corkery’s chapter exists to keep a named, citable death tally and practical-danger framing in the literature graph. Soft CTA: /safety-and-screening → /apply. Pair with Ona AE systematic review (/blog/ona-2022-ibogaine-adverse-events-review), Litjens toxicity (/blog/litjens-brunt-2016-ibogaine-toxicity), Schep dose-safety (/blog/schep-2016-ibogaine-poisoning), and mortality hub (/blog/ibogaine-mortality-cardiac-risk).

What was published

| Feature | Accurate description | |---------|----------------------| | Citation | Corkery J.M. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers. *Prog Brain Res*. 2018;242:217–257. doi 10.1016/bs.pbr.2018.08.005. PMID 30471681 | | Type | Invited review/chapter (fatality update + risk-benefit) | | Fatality update | 33 known deaths discussed, including 5 UK cases (per chapter abstracting) | | Balance | Potential benefits of further research vs serious AEs from undiagnosed conditions / concomitant drugs / non-medical settings | | Forward look | Better risk assessment; accurate recording of outcomes including deaths; notes 18-MC congener interest as potentially safer research path (preclinical/clinical development—not approved consumer therapy) | | What it is not | RCT; personal prognosis calculator; psychoactive IV brand proof; cure claim |

Verification note (best 2016–2020 cite): Corkery 2018 PBR is the preferred single fatality-analysis chapter in-window. Alper et al. 2012 *J Forensic Sci* remains the classic earlier forensic series (outside preferred window but historically foundational). Later AE systematic reviews (Ona 2022) update adverse-event landscape without replacing Corkery’s death-tally chapter role.

Methods (plain language)

Corkery synthesizes published case reports, forensic literature, and treatment-context reports into a narrative risk-benefit chapter. Chapter evidence is only as complete as public reporting—under-ascertainment of deaths in informal settings is a known problem the author flags by calling for better recording.

Key points (no hype)

• Known publicly reported ibogaine-associated deaths are not zero; Corkery’s update puts the compiled figure at 33 as of that chapter.
• Many events occur in settings without robust medical monitoring.
• Undiagnosed cardiac disease, electrolyte problems, CYP2D6/polypharmacy interactions, and product quality issues recur as practical danger themes across the fatality literature.
• Purported anti-addictive benefits still lack the controlled trial standard regulators require.
• Congeners such as 18-MC are discussed as research avenues with potentially better therapeutic index—LABEL: not an approved substitute patients can buy today (/blog/ibogaine-18-mc-analog-preclinical).

Honest reading: A death tally is a reason to demand ECG/telemetry literacy, not a reason to romanticize underground dosing.

Bridge to clinical cardiac spokes

| Corkery theme | Clinical echo on this site | |---------------|----------------------------| | Fatalities temporally associated with ingestion | /blog/ibogaine-mortality-cardiac-risk | | Need for risk assessment | /safety-and-screening | | QT/arrhythmia biology | /blog/knuijver-2021-ibogaine-qtc-safety, /blog/alper-herg-ibogaine-cardiac-mechanism | | AE taxonomy 2015–2020 | /blog/ona-2022-ibogaine-adverse-events-review |

Route honesty & entity clarity

Fatality chapters pool oral and often poorly documented routes. They do not prove that physician-supervised psychoactive IV ibogaine infusion is efficacious—or that route change alone abolishes hERG/QTc risk. Oral≠IV remains mandatory (/blog/ibogaine-oral-vs-iv). Entity: /what-is-ibogaine-infusion.

Limits

| Limit | Why it matters | |-------|----------------| | Passive/chapter synthesis | Depends on published cases; missing cases possible | | Heterogeneous products/doses | Hard to map dose–death curves cleanly | | Confounded decedents | Polypharmacy, comorbidities | | Not efficacy data | Cannot be flipped into success marketing |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Deaths mean never research” | Over-simple—chapter calls for better research *and* caution | | “Medical setting = zero risk” | False—risk mitigated, not erased | | “Proves IV brand safe/effective” | False | | Justifies screening-first CTA? | Yes |

Soft CTA

Practical dangers checklist (editorial translation)

Corkery’s “practical dangers” language maps to operational screening questions families should ask any program—U.S.-adjacent or abroad:

1. Baseline ECG / QTc and plan for continuous monitoring (/blog/ibogaine-ecg-pre-infusion-checklist).
2. Electrolytes (especially potassium and magnesium) before dosing.
3. Medication reconciliation for QT-prolonging drugs and CYP2D6 inhibitors (/blog/ibogaine-drug-interactions-qtc, /blog/ibogaine-cyp2d6-metabolism).
4. Product identity/purity (HCl vs crude bark/extract).
5. On-site emergency capability (defibrillation, ACLS-capable staff)—not “a friend with a pulse oximeter.”
6. Honest aftercare plan because relapse and polypharmacy after discharge still kill (/blog/ibogaine-aftercare-integration).

If a seller cannot answer these, Corkery’s chapter is your reason to walk away (/blog/cheap-ibogaine-clinic-red-flags).

How later reviews cite Corkery

Toxicity and AE papers after 2018 often lean on Corkery’s compiled death count as the public tally anchor (e.g., discussions noting ~33 publicly reported deaths with later case increments). That does not mean the true global count is fully known—under-reporting in informal settings remains plausible. For SEO, say “at least the publicly compiled figure Corkery updated to 33 as of the 2018 chapter,” not “exactly 33 forever.”

If fatality numbers are why you opened this tab, do not skip the operational page: /safety-and-screening → /apply only after cardiac literacy for supervised IV ibogaine infusion questions.

FAQ

What is the best 2016–2020 Corkery fatality cite? Corkery J.M., *Prog Brain Res* 2018;242:217–257. doi **10.1016/bs.pbr.2018.08.005**. PMID **30471681**.

How many deaths does Corkery update to? **33** known deaths discussed, including **5** in the UK (per chapter).

Is Corkery 2018 a clinical trial? No—review/chapter synthesizing fatalities and practical dangers.

Does a medical clinic erase all risk? No. Screening and monitoring reduce but do not eliminate QTc/arrhythmia risk.

Does this prove IV ibogaine infusion efficacy? No.

What about 18-MC? Research congener interest—not an approved consumer therapy (/blog/ibogaine-18-mc-analog-preclinical).

Is ibogaine FDA-approved? No. Schedule I.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Sources (selected)

1. Corkery J.M. *Prog Brain Res*. 2018;242:217–257. doi: 10.1016/bs.pbr.2018.08.005. PMID: 30471681.
2. Alper K.R., Stajić M., Gill J.R. Fatalities temporally associated with the ingestion of ibogaine. *J Forensic Sci*. 2012;57:398–412. (foundational earlier series).
3. Ona G. et al. *Psychopharmacology*. 2022. doi: 10.1007/s00213-021-05964-y.
4. Litjens R.P.W., Brunt T.M. *Clin Toxicol*. 2016. doi: 10.3109/15563650.2016.1138226.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Corkery 2018 is a fatality/risk chapter—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.